How should I evaluate for primary myelofibrosis?

Evaluation for Primary Myelofibrosis

Establish the diagnosis of primary myelofibrosis through bone marrow biopsy with reticulin/collagen fibrosis grading, complete blood count, peripheral blood smear, comprehensive molecular testing for JAK2/CALR/MPL driver mutations, next-generation sequencing for prognostic mutations, and cytogenetic analysis, while simultaneously excluding other causes of myelofibrosis. 1, 2

Diagnostic Algorithm

Step 1: Clinical and Laboratory Assessment

Begin with specific clinical features that distinguish PMF:

• Splenomegaly (palpable on physical exam or imaging)
• Constitutional symptoms: fatigue, night sweats, weight loss, fever
• Anemia not explained by other conditions
• Leukocytosis ≥11 × 10⁹/L
• Elevated LDH
• Leukoerythroblastosis on peripheral blood smear 1, 3

Obtain complete blood count and peripheral blood smear looking specifically for leukoerythroblastic picture (nucleated red blood cells and immature myeloid cells in circulation). 4

Step 2: Bone Marrow Evaluation (Essential)

Bone marrow biopsy is mandatory—aspiration alone is insufficient. 4, 5 The biopsy must assess:

For Overt PMF:

• Megakaryocyte proliferation with atypical morphology (small to large, aberrant nuclear/cytoplasmic ratio, hyperchromatic irregularly folded nuclei, dense clustering)
• Reticulin fibrosis grade 2-3 (on 0-3 scale) or collagen fibrosis
• Granulocytic proliferation
• Often decreased erythropoiesis 1

For Pre-fibrotic PMF (Pre-PMF):

• Same megakaryocytic proliferation and atypia
• No significant reticulin fibrosis (grade 0-1 only)
• Increased age-adjusted bone marrow cellularity
• Granulocytic proliferation with decreased erythropoiesis 1

Critical pitfall: Pre-PMF can mimic essential thrombocythemia clinically with isolated thrombocytosis, but the megakaryocyte morphology and clustering pattern are distinctly different. 3, 4

Step 3: Molecular and Genetic Testing (Required)

Driver mutation testing (perform on all patients):

• JAK2V617F mutation
• CALR (calreticulin) mutations
• MPL mutations

Approximately 90% of PMF patients have one of these driver mutations. 3, 4 The remaining 10% are "triple-negative" and require additional workup.

For triple-negative cases:

• Cytogenetic analysis (karyotype) to identify clonal markers
• If negative, consider next-generation sequencing for other somatic mutations to establish clonality 1, 4

Prognostic mutation panel (essential for risk stratification):

Order comprehensive NGS testing for high-risk mutations that independently predict survival:

• ASXL1 (inferior overall survival and leukemia-free survival)
• EZH2 (inferior overall survival)
• SRSF2 (inferior overall and leukemia-free survival)
• IDH1/2 (inferior leukemia-free survival)
• U2AF1-Q157 (predicts inferior survival)
• TP53 (associated with leukemic transformation)
• RAS/CBL (predict ruxolitinib resistance) 2, 3

Prognostic significance of driver mutations:

• CALR mutations (especially Type 1/Type 1-like): Best prognosis, improved survival compared to JAK2 or triple-negative
• JAK2V617F and MPL mutations: Intermediate prognosis, higher thrombosis risk
• Triple-negative: Inferior leukemia-free survival and overall survival 2, 3

Step 4: Cytogenetic Risk Stratification

Perform conventional karyotyping to identify:

Very high-risk abnormalities:

• Chromosome 7 deletion (-7)
• inv(3), i(17q)
• +21, +19
• 12p-, 11q-

Favorable risk abnormalities:

• Normal karyotype
• Isolated +9, 13q-, 20q-, 1q abnormalities
• Loss of Y chromosome 2, 3

Step 5: Exclude Other Causes

Must rule out:

• BCR-ABL1+ chronic myeloid leukemia (perform BCR-ABL1 testing)
• Polycythemia vera (check for prior PV diagnosis, hemoglobin/hematocrit criteria)
• Essential thrombocythemia (different megakaryocyte morphology)
• Myelodysplastic syndromes (assess dysplasia, blast percentage)
• Autoimmune myelofibrosis (check autoimmune markers, inflammatory conditions)
• Other reactive causes of fibrosis (infections, metastatic disease) 1, 4

Step 6: Symptom Burden Assessment

Use the MPN-SAF Total Symptom Score (MPN-SAF TSS) at baseline:

• Patient-rated 0-10 scale for 10 symptoms (fatigue, early satiety, abdominal discomfort, inactivity, concentration problems, night sweats, itching, bone pain, fever, weight loss)
• Total score 0-100
• Establishes baseline for treatment monitoring 2

Diagnostic Criteria Summary

For Overt PMF, all 3 major criteria plus ≥1 minor criterion required:

Major criteria:

1. Megakaryocyte proliferation/atypia with reticulin/collagen fibrosis grade 2-3
2. Not meeting WHO criteria for other myeloid neoplasms
3. JAK2/CALR/MPL mutation OR other clonal marker OR absence of reactive fibrosis

Minor criteria (need ≥1):

• Anemia
• Leukocytosis ≥11 × 10⁹/L
• Palpable splenomegaly
• Elevated LDH
• Leukoerythroblastosis 1

For Pre-PMF: Same criteria but with grade 0-1 fibrosis only and required megakaryocyte changes with increased cellularity and granulocytic proliferation. 1

Common Pitfalls

• Inadequate bone marrow sample: Aspiration alone misses fibrosis—biopsy is mandatory
• Confusing pre-PMF with ET: Look carefully at megakaryocyte morphology and clustering patterns
• Missing triple-negative cases: Always perform comprehensive molecular testing even when driver mutations are negative
• Incomplete prognostic workup: NGS panel and cytogenetics are not optional—they determine treatment strategy and transplant timing 3, 4